Panelists discuss how bispecific antibody therapies are revolutionizing multiple myeloma treatment by providing highly effective, accessible options for heavily pretreated patients while addressing key implementation challenges including patient selection, sequencing strategies, safety management protocols, and the transition from academic centers to community-based care delivery.
EP. 1: Treatment Decision-Making in Multiple Myeloma at First and Subsequent Relapses
September 30th 2025Panelists discuss how patient preferences for treatment-free intervals are increasingly important in therapy selection, with bispecifics offering potential for response-adapted dosing and early discontinuation while maintaining remissions.
EP. 2: Navigating Novel Therapies: ADCs, BsAbs, and CAR T in RRMM
September 30th 2025Panelists discuss how bispecifics are reversing the historical paradigm of diminishing returns in relapsed/refractory multiple myeloma, achieving 60% to 70% response rates lasting over a year in heavily pretreated patients.
EP. 3: Sequencing Strategies and Patient Selection for Bispecific Antibodies in RRMM
October 7th 2025Panelists discuss how CAR T-cell therapy should generally precede bispecifics when possible due to T-cell exhaustion concerns, though they agree there are virtually no absolute contraindications to bispecific therapy.
EP. 4: Real-World Efficacy and Safety Protocols for Bispecific Antibodies
October 7th 2025Panelists discuss how real-world data consistently show bispecific efficacy matching clinical trial results despite treating higher-risk patients, and how prophylactic interventions have reduced cytokine release syndrome severity.
EP. 5: Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies
October 14th 2025Panelists discuss how talquetamab’s unique skin and taste toxicities are manageable through dose modifications and supportive care, with IVIG prophylaxis being crucial for BCMA-targeted but not necessarily GPRC5D-targeted therapies.
EP. 6: Operationalizing Step-Up Dosing in Outpatient and Inpatient/Outpatient Hybrid Setting
October 14th 2025Panelists discuss how step-up dosing has successfully transitioned from inpatient-only to hybrid and outpatient models using prophylactic tocilizumab and standardized protocols for managing cytokine release syndrome.
EP. 8: Patient With RRMM, Cytopenias, COPD, and Progressive Bone Disease
October 21st 2025Panelists discuss how a triple class–exposed patient with comorbidities like COPD represents an ideal candidate for BCMA-directed bispecific therapy over CAR T-cell therapy due to the ability to titrate dosing and manage respiratory infection risks.